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Abstract
The tumor suppressor p53 was previously shown to markedly up-regulate the expression of the PRODH gene,
encoding the proline dehydrogenase (PRODH) enzyme, which catalyzes the first step in proline degradation. Also
PRODH2, which degrades 4-hydroxy-L-proline, a product of protein (e.g. collagen) catabolism, was recently
described as a p53 target. Here, we confirmed p53-dependent induction of endogenous PRODH in response to
genotoxic damage in cell lines of different histological origin. We established that over-expression of TAp73β or
TAp63β is sufficient to induce PRODH expression in p53-null cells and that PRODH expression parallels the
modulation of endogenous p73 by genotoxic drugs in several cell lines. The p53, p63, and p73-dependent
transcriptional activation was linked to specific intronic response elements (REs), among those predicted by
bioinformatics tools and experimentally validated by a yeast-based transactivation assay. p53 occupancy
measurements were validated in HCT116 and MCF7 human cell lines. Conversely, PRODH2 was not responsive to
p63 nor p73 and, at best, could be considered a weak p53 target. In fact, minimal levels of PRODH2 transcript
induction by genotoxic stress was observed exclusively in one of four p53 wild-type cell lines tested. Consistently, all
predicted p53 REs in PRODH2 were poor matches to the p53 RE consensus and showed very weak
responsiveness, only to p53, in the functional assay. Taken together, our results highlight that PRODH, but not
PRODH2, expression is under the control of p53 family members, specifically p53 and p73. This supports a deeper
link between proteins of the p53-family and metabolic pathways, as PRODH modulates the balance of proline and
glutamate levels and those of their derivative alpha-keto-glutarate (α-KG) under normal and pathological (tumor)
conditions.
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Introduction
The p53 protein exerts its tumour suppressive function acting
primarily as a transcription factor, that controls the expression
of a large and ever increasing number of target genes in
response to a variety of stresses [1–3]. Well known outcomes
are cell cycle arrest, DNA repair, apoptosis, but more recently
p53 involvement in the induction of autophagy and regulation of
metabolism has also been described [4,5].
Historically, p53 represents the founder member of the p53
family, to which also p63 and p73 belong. These proteins share
the highest level of homology in the DNA binding domain and
often recognize the same REs in the promoter of target genes.
However, the pattern of transcribed genes upon induction of
the different family members does not overlap completely [6]
and neither do the biological functions, as exemplified by their
different roles during embryonic development [7].
To complicate matters, the various p53 family members can
also influence each other’s function and transactivation activity
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through a complex network created by the different
transactivation efficiency of the various isoforms and the
presence of “p53” REs in their own regulatory regions [8,9].
Clearly, there is a complex transactivation network within the
p53 family and between the p53 family and other transcription
factors in the regulation of target genes [10,11]. The canonical
p53 RE consists of two decameric half-sites separated by a
0-13 base spacer (n): RRRCWWGYYY-(n)-RRRCWWGYYY
(R = purine; W=A/T; Y = pyrimidine) [12]. Moreover, non-
canonical binding sites have been identified comprising half-
sites and three quarter sites, expanding the universe of
potential downstream target genes which may be regulated by
p53 [13].
This underlines the importance of understanding how
transactivation specificity arises through the mapping and the
characterization of the REs present in target genes. Regulatory
regions within genes are a complex field of investigation. Thus,
their thorough characterization in terms of sequence and
location may help assessing coordinated regulation by
transcription factors, as well as cell type and cell context (type
of stress, kinetics) dependencies on gene expression,
ultimately contributing to define gene functions [11,14].
Several years ago Polyak and colleagues identified PIG6,
also known as PRODH/POX, among the apoptotic genes
induced by p53 after adriamycin treatment [15]. Nevertheless,
a systematic search and validation of the p53 REs in this gene
have never been carried out. As a consequence, PRODH is not
considered as a proven p53 target in most of the published
reviews [1,2]. Since its discovery, evidence has been
accumulating on the role that proline dehydrogenase, the
protein encoded by the PRODH gene, could play in
suppressing tumorigenesis, suggesting its contribution as an
apoptosis effector through ROS induction [16]. Very recently, a
PRODH-dependent induction of autophagy has also been
described [17]. The biochemical function of PRODH (EC
1.5.99.8) is the oxidation of proline to Δ'-pyrroline-5-carboxylic
acid (P5C), which is converted to glutamate by P5C
dehydrogenase (EC 1.5.1.12). Notably, also the gene encoding
P5C dehydrogenase, ALDH4, has been reported to be a target
of p53 [18], suggesting the importance of the proline to
glutamate conversion in mediating p53 functions.
More recently, some Authors showed that also 4-hydroxy-L-
proline (OH-proline) dehydrogenase (EC 1.1.1.104), encoded
by the PRODH2 gene, was induced by p53 [19], a result,
however, not confirmed by others [20]. Like proline, OH-proline,
the substrate of OH-proline dehydrogenase, is present in some
cellular, extracellular and dietary proteins, and represents an
abundant source of substrate. While downstream metabolites
of proline can impact several aspects of cellular metabolism,
OH-proline derivatives compounds can be used to generate
ATP or ROS, but do not have anaplerotic or regulatory
functions [19].
The aim of this study was to identify and to validate the p53
REs present in the PRODH and PRODH2 genes and to
investigate their responsiveness also to the other p53 family
members. Here we show that four intronic p53 REs, located in
introns 2 and 3 of the PRODH gene, are the most active
among the REs examined. Interestingly, one of them is
efficiently transactivated by all p53 family members.
Conversely, the putative REs identified in the PRODH2 gene
respond poorly even in the presence of high p53 levels and are
inactive with p63 and p73, as revealed with a yeast functional
assay. Moreover, PRODH2 expression was weakly detectable
following genotoxic stress only in one of the p53 wild-type cell
lines we tested, consistent with heterogeneous results in the
literature [19,20].
Materials and Methods
Reagents
Doxorubicin (DOXO) and 5-fluorouracil (5FU) were from
Sigma Aldrich (Milan, Italy); Nutlin-3A was purchased from
Alexis Biochemicals (Enzo Life Sciences, Exeter, UK). All
oligonucleotides were from Eurofins MWG Operon (Ebersberg,
Germany). Bacteriological reagents (Bactoagar, Yeast extract,
Peptone) were from DIFCO (BD Biosciences, Milan, Italy) and
all other reagents were from Sigma Aldrich (Milan, Italy).
Cell lines and treatments
The human breast adenocarcinoma-derived MCF7 and
MDA-MB-231 cell lines were obtained from the InterLab Cell
Line Collection bank, ICLC (Genoa, Italy); the colon
adenocarcinoma HCT116 (p53+/+) cell line and its p53−/−
derivative were a gift from B. Vogelstein (The Johns Hopkins
Kimmel Cancer Center, Baltimore, Maryland, USA) [21]. LoVo
colon adenocarcinoma cells were a gift from M. Broggini
(Istituto Farmacologico Mario Negri, Milan, Italy) [22]; Rh30
rhabdomyosarcoma cell line was donated by Dr. A. Rosolen
(Clinica di Oncoematologia Pediatrica, University of Padua,
Italy) [23]; the hepatocellular carcinoma derived Mahlavu and
HepG2 cell lines were a generous gift of Dr. M.L. Neri
(University of Ferrara, Italy) [24] and A. Provenzani (University
of Trento, Italy) [25], respectively. Finally, HaCat immortalized
keratinocytes, JHU-011 and JHU-029 head and neck
squamous cell carcinoma (HNSCC) cell lines were obtained
from the Sidransky lab at Johns Hopkins University (Baltimore,
MD, USA) [26–28]. Cells were maintained in DMEM or RPMI
supplemented with 10% FCS, 1% glutamine and antibiotics
(100 units/ml penicillin plus 100 µg/ml streptomycin) and
routinely checked to exclude the presence of mycoplasms.
To study PRODH expression in response to endogenous
p53 induction or stabilization, or endogenous p63 and p73
modulation, cells were seeded at 80% confluence and treated
with genotoxic agents or Nutlin-3A at the indicated
concentrations for 16 hours. For transient transfection
experiments with HCT116 p53-/-, 7 x 105 cells were seeded in
6-well plates 24 hours before transfection to reach ~70%
confluence on transfection day. Cells were transfected using 2
µg plasmid DNA/well and the TransIT-LT1 transfection reagent
(Mirus, Milan, Italy) according to the manufacturer’s
instructions. Human p53 was expressed from the pC53-SN3
plasmid [29], while p63β and p73β cDNAs were expressed
from pCDNA3.1 [11]. pCDNA3.1 vector with no insert (empty
vector) was used as negative control in each transfection. All
mammalian constructs were extracted from XL1blue E. coli
cells using the endotoxin free PureYield plasmid midi-prep kit,
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according to the manufacturer’s protocol (Promega, Milan,
Italy). In all experiments, cells were harvested 24 hours after
transfection, trypsinized and collected for RNA extraction.
Antibodies and western blotting
Soluble protein extracts were obtained by mechanically
scraping the cells from 100 mm plates in PBS containing 5 mM
Na 2EDTA, followed by cell counting and resuspension in RIPA
buffer supplemented with protease inhibitors (PMSF,
benzamidine, aprotinin, and leupeptin). After 1 hour incubation
at 4°C under rotation and centrifugation to remove the insoluble
fraction, the proteins’ concentration was evaluated using the
Bradford reagent, and a standard curve obtained with bovine
serum albumin. Twenty to 150 µg of extract were used for
SDS–PAGE, depending on the protein to be immunodetected.
Immunoblot analyses were performed using the i-Blot semi-dry
system with nitrocellulose membranes (InVitrogen, Life
Technologies, Milan, Italy) and detected with the ECL Select
chemiluminescent substrate (GE Health Care, Milan, Italy).
When necessary, blots were stripped by standard methods and
re-probed with the indicated antibody. Mouse monoclonal DO-1
anti-p53 antibody (sc-126) and 4A4 anti-p63 (sc-8431) were
from Santa Cruz Biotechnology (Heidelberg, Germany), while
mouse monoclonal ER-15 anti-p73 antibody (OP 109) was
from Calbiochem-Millipore. Rabbit anti β-actin (A2066) from
Sigma (Milan, Italy) or 3F3-G2 mouse monoclonal anti β-tubulin
(sc-53140) from Santa Cruz were used for normalization.
Analysis of PRODH and PRODH2 transcript levels
To quantify PRODH and PRODH2 mRNAs following
treatments or transfections, cells were harvested and washed
once with PBS. Total RNA was extracted using the RNeasy Kit
(Qiagen, Milan, Italy) according to the manufacturer’s
instructions. For real-time quantitative PCR (qPCR), cDNA was
generated from 2 µg of RNA by using the RevertAid First
Strand cDNA Synthesis Kit (Fermentas, Milan, Italy) or the
iScript Reverse Transcription Supermix for qPCR (Biorad,
Milan, Italy). qPCR was performed on a RotorGene 3000
thermal cycler (Corbett Life Science, Ancona, Italy) or on a
StepOne thermal cycler (AB, Milan, Italy) using the KAPA
Probe Fast Universal 2X qPCR Master Mix (Resnova, Rome,
Italy) with Taqman assays (AB, Milan, Italy) or the Sso
Advanced Sybr Green Supermix (Biorad, Milan, Italy). Primers
are reported in Table S1. Relative mRNA quantification was
obtained using the ΔΔCt method, where the glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) or the β2-microglobulin
(B2-M) genes served as internal control. P21, NOXA, PUMA or
COL18A1 were used as controls for the efficacy of modulation
of p53 family members by the specific treatment or
transfection.
Construction of yeast reporter strains and media
Nine different Saccharomyces cerevisiae reporter strains
were constructed, containing the firefly luciferase gene under
the control of the p53 RE found by bioinformatics tools (see
below) in the PRODH and PRODH2 genes. To insert the
putative p53 RE upstream of the luciferase reporter gene the
“delitto perfetto” approach for in vivo mutagenesis was used
[30], starting from the available master reporter strain yLFM-
ICORE. The master strain contains the luciferase cDNA
integrated in the yeast genome downstream a minimal
promoter derived from the CYC1 gene. The counter selectable
ICORE cassette is located 5’ to the minimal promoter and
confers high targeting efficiency of the locus by
oligonucleotides that contain the desired RE sequences
flanked by appropriate homology regions (Table S2) [30]. The
recombinant yeast strains were checked by colony PCR and
direct sequencing for proper positioning of the inserted REs
(BMR Genomics, Padua, Italy).
Yeast cells were grown in YPDA medium (1% yeast extract,
2% peptone, 2% dextrose with the addition of 200 mg/L
adenine). For plating, YPDA medium was supplemented with
2% bactoagar, while selective minimal plates lacking
tryptophan or leucine but containing adenine (200 mg/L) and
dextrose as carbon source were used to isolate transformant
clones with expression vectors for p53 family proteins. 5-
Fluoro-orotic acid (FOA) and geneticin (G418) were added to
the plates when necessary [30].
Constructs for the expression of p53 family members in
S. cerevisiae
To express members of the p53 family in yeast, the pTSG-
(TRP1) or pLSG- (LEU2) based constructs, harbouring
respectively p73β and p63β cDNAs (TA isoforms) under the
control of the GAL1,10 inducible promoter, were used [13,31].
This promoter allows to modulate the expression of the
proteins under study by varying the galactose concentration in
the culture medium The wild-type p53 cDNA was similarly
expressed using the pLS89 expression vector (TRP1) [31].
Empty vectors pRS-314 or pRS-315 were used as controls;
these vectors contain respectively the TRP1 (as pTSG-) or
LEU2 (as pLSG-) yeast selectable markers.
Luciferase assays in yeast
To measure the transactivating capacity of p53 family
members on the putative p53 REs identified in PRODH and
PRODH2 genes, the expression vectors described above were
transformed into the yLFM-RE strains using the lithium acetate
method. After transformation the yeast strains were grown on
minimal medium lacking tryptophan or leucine but containing
adenine (200 mg/L) and dextrose as carbon source, to keep
the expression of p53 family members inhibited. After 2-3 days
at 30°C, transformants were streaked onto the same type of
plates and grown for an additional day. For each reporter
strain, the basal luciferase activity was measured from the
empty vectors pRS314- or pRS315-transformed colonies. As a
positive control, the yeast strain carrying one of the p53 REs
from the p21 gene (p21-5’: GAACATGTCC-CAACATGTTG)
was used. This strain has been previously described [32].
Transformant colonies were grown in 100 µL of selective
medium containing raffinose as the sole carbon source in a
transparent 96-well plate for 16-24 hours at 30°C. Different
concentrations of galactose (0.008% and 1%) were used to
induce low or high levels of expression of the p53 family
members. OD600 was directly measured in the multi-well plate
to normalize for cell density using a multilabel plate reader
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(Infinite M200-Pro, Tecan, Milan, Italy). Ten µL of cells
suspension were transferred to a white 384 plate (BrandTech
Scientific Inc., Essex, CT, USA) and mixed with an equal
volume of PLB buffer 2X (Passive Lysis Buffer, Promega). After
15 minutes of shaking at room temperature, 10 µL of Firefly
luciferase substrate (Bright Glo Luciferase Reporter Assay,
Promega) were added. Luciferase activity was measured and
results were expressed as fold of induction compared to empty
vectors.
Chromatin immunoprecipitation experiments in HCT116
and MCF7 cell lines.  Chromatin immunoprecipitation (ChIP)
assays were performed as previously described [33], using the
EZ Magna ChIP kit (Upstate Biotechnology, Millipore, Lake
Placid, NY, USA). Briefly, MCF7 or HCT116 p53+/+ and p53-/-
cells were plated onto 150 mm dishes, let to grow for one day
and treated with 1.5 µM doxorubicin for 16 hours or left
untreated. Cells were then cross-linked with 1% formaldehyde
for 10 minutes at 37°C and treated subsequently with 125 mM
glycine for 5 minutes. Samples were processed following the
manufacturer’s instructions. Cell lysates were then sonicated
using conditions that enabled us to evaluate the distinct
contribution of the different REs. Sonication was done using a
Misonix 4000 instrument equipped with a multiplate horn
(Misonix, Qsonica LLC, Newtown, CT, USA). Samples were
sonicated using twelve cycles of 20 seconds pulses at 80% of
amplitude with a 40 seconds pause in-between and the
accuracy of sheared chromatin fragments was checked on a
2% agarose gel. The p53-specific monoclonal antibody DO-1
(Santa Cruz Biotechnology, Milan, Italy) and magnetic Protein
G beads were used in the ChIP assay. In MCF7, the mouse
IgG (Santa Cruz Biotechnology) was used as background,
while the DO-1 binding in the HCT116 p53-/- cell line was
considered as background for the occupancy in the HCT116
p53+/+ cells. Once reverted the crosslinks, PCR amplifications
were performed on immunoprecipitated and purified chromatin
using primers to amplify specific regions in the PRODH
promoter and introns, in the CCNB1 gene, that does not
contain any p53 REs (No Binding Site, NBS: negative control)
and in the P21 gene (positive control) (see Table S1 for a list of
oligonucleotide primers used in this work). Furthermore, qPCR
was used to quantify the change in site occupancy in DOXO
treated compared to untreated samples. The qPCR reaction
was performed with 2 µL of each sample and using the Power
SYBR® Green PCR Master Mix (Applied Biosystems, Foster
City, CA, USA), following manufacturer’s procedures. The
results are indicated as percent of input DNA.
Bioinformatics analysis
Sequences of the human PRODH and PRODH2 reference
mRNAs (NM_016335.4 and NM_021232.1, respectively) were
retrieved from NCBI (http://www.ncbi.nlm.nih.gov/nucleotide),
and the genomic organization was obtained with the UCSC
Blat algorithm at http://genome.ucsc.edu/, followed by
extension of the promoter region retrieved, using the function
“gene sorter” at UCSC.
To search for the p53 REs in the PRODH and PRODH2
genes, the following sites were consulted:
• TESS (http://www.cbil.upenn.edu/tess.);
• p53MH algorithm (http://linkage.rockefeller.edu/ott/
p53MH.htm.) [34];
• p53 FamTaG (http://p53famtag.ba.itb.cnr.it/index.php.) [35];
• TFBIND (http://tfbind.hgc.jp/) [36].
Results
1: PRODH levels increase upon genotoxic stress or p53
stabilization
To confirm that PRODH is inducible by genotoxic stress via
p53, we treated cell lines of different origin (colon, breast, liver),
known to harbour wild-type p53, with DOXO or 5-FU. PRODH
transcript was readily induced by DOXO or 5-FU in all cell lines
tested except in HCT116 p53-/- cells, confirming that induction
was indeed p53 dependent (Figure 1). Induction by DOXO was
particularly evident in the HepG2 cell line. PRODH expression
also increased in a dose dependent manner when HCT116
p53+/+ cells were treated with the p53 stabilizer Nutlin-3A
(Figure 1).
As PRODH induction occurred upon increase of p53 levels
due to either genotoxic stress or treatment with a p53 stabilizer,
we suggest that it is indeed p53 dependent.
2: The PRODH gene contains numerous putative p53
REs
A combination of four bioinformatic tools for identifying p53
specific or general transcription factors binding sites (p53MH,
p53FamTag, Tess, TFBIND) along with manual search was
used to scan the PRODH gene. Nine putative p53 REs were
identified and named according to their distance from the
Transcription Start Site (TSS), based on reference sequence
NM_016335.4 (Table 1).
Six REs were selected for validation, based on the
evaluation of the following parameters: number and position of
mismatches with respect to the consensus, presence of a
spacer sequence between the two decameric sites, and
position in the gene (Table 1). Three putative REs were
excluded from further analysis: +6.4, which had an 8 bp spacer
and mismatches in both decamers, involving in both cases a
base near the core motif; +14.3, which had a 2 bp spacer and,
again, mismatches close to the core in both decamers; and
+15.8, which consisted of a three quarter site where the quarter
site was separated from the half-site by a 5 bp spacer. Since
we previously observed that the presence of mismatches and
spacer length dramatically decrease RE functionality [37], and
considering the distance from the TSS, these REs were not
further investigated. Among the selected REs, two were
located in the promoter of the PRODH gene, at positions -3.1
and -0.9 kb from TSS; the latter has already been described
[38] and was investigated, although it did not completely fulfil
the chosen parameters. The other REs were located in intron 2
(+1.7, +2.8 and +4.7 kb) and 3 (+6.8 kb), respectively. The
latter RE, +6.8, falls within a genomic region previously
identified in a ChIP -sequencing experiment but not further
characterized [39]. In that paper, the RE was reported to be in
intron 1, although according to a more recent genomic
assembly and the PRODH mRNA version NM_016335.4 used
in the present work, it is located in intron 3.
PRODH and PRODH2 Regulation by p53 Family Members
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The two REs in the promoter contained only one half-site
with either one (-3.1) or no (-0.9) mismatches (Figure 2A). An
additional half-site with two mismatches, one of which involving
a base in the CWWG core sequence, was present in the -3.1
RE, separated from the first half-site by a 5 bp spacer; in the
-0.9 RE, a quarter site with one mismatch and a half-site with
three mismatches (that can alternatively be considered a
quarter site with one mismatch) were present, separated by the
first half-site by 7 and 5 bp spacers, respectively (Figure 2A).
Among the intronic REs, two (+1.7 and +6.8) had no spacers,
while the +4.7 had a 3 bp spacer; the +4.7 and +6.8 REs had a
consensus half-site and a second half-site with two
mismatches outside the CWWG core motif, while the +1.7 had
mismatches (one or two) in each half-site (Figure 2A). The +2.8
RE was identified as a full site composed of two half-sites
(GctCATGCCT-AGGCATGgTg) by the TFbind software. Upon
careful analysis of the nearby sequence, this RE turned out to
be surrounded by other half-sites, thus constituting a cluster
with a total of 5 half-sites, of which the 3 central contained a
CATG core and no bp spacer, while the two external half-sites
were separated from the central 3 REs by 3 bp spacers (Figure
2A). Each of the 5 half-sites in the +2.8 RE contained at least 2
mismatches, none involving the CWWG core motif of the
consensus. Interestingly, the +6.8 was the only RE identified by
the p53SCAN algorithm in the genomic region encompassing
the PRODH gene [40].
Figure 1.  Genotoxic stress and p53 stabilization result in a p53-dependent increase of PRODH transcript levels.  HCT116
p53+/+, HCT116 p53-/-, MCF7, HepG2 and LoVo cell lines were treated with the genotoxic compounds Doxorubicin (DOXO, 0.5, 1 or
where not indicated, 1.5 µM), 5-Fluorouracil (5FU, 375 µM) or with the p53 stabilizer Nutlin-3A (Nutlin, 5 or 10 µM) for 16 hours
before proceeding to total RNA extraction, cDNA preparation and real time q-PCR. The established p53 target gene P21 is shown
for comparison (lighter bars). Bars indicate the average folds of induction obtained in treated versus untreated cell samples, plotted
together with the standard deviation of three biological replicates. The values obtained in untreated cell lines were set to 1 and
shown in the figure as a horizontal broken line.
doi: 10.1371/journal.pone.0069152.g001
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3: The p53 family members differentially transactivate
from the PRODH REs in yeast
Six yeast reporter strains, corresponding to the six selected
REs in the PRODH gene (-3.1; -0.9; +1.7; +2.8; +4.7; +6.8,
Figure 2A), were constructed using the “delitto perfetto”
approach [30,41]. A well-established yeast transactivation
assay was then applied to analyze the induction of the
luciferase reporter gene upon expression of p53, p63β or p73β
proteins. An isogenic yeast strain carrying the P21-5’ RE was
used as positive control [32]. The results are presented as
mean fold of induction over empty vector that was used as
negative control. The expression of the p53 family members
was regulated by using the galactose inducible promoter
GAL1,10. Two different galactose concentrations were
exploited to induce different levels of the transcription factors.
The four intronic REs (+1.7, +2.8, +4.7 and +6.8) were induced
by p53 in a dose dependent manner and showed strong
response at the higher level of induction (1% galactose) (Figure
2B). At moderate induction (0.008% galactose), the +2.8, +4.7
and +6.8 already showed at least a 35-fold increase in
luciferase activity above background. Overall, the levels of p53-
dependent induction of the intronic REs were comparable to
those obtained with the positive control strain, bearing the
P21-5’ RE, which has been previously shown to be strongly
induced by the p53 family members in yeast [32]. The REs in
the promoter (-3.1 and -0.9) instead, showed no (-3.1) or
extremely weak (2.5-fold, -0.9) induction over the basal level
even at 1% galactose, suggesting lack of responsiveness to
p53 (Figure 2B). Also the other p53 family members could
weakly transactivate luciferase reporter expression from some
REs, but only at 1% galactose. More specifically, the +1.7, +2.8
were very weakly transactivated upon p63β but not p73β
expression, while the + 6.8 RE was transactivated following
p63β or p73β expression (5 to 10-fold) (Figure 2B). At low
galactose induction of p63β and p73β, no detectable increase
in luciferase activity was observed in any of the PRODH REs
(Figure 2B).
4: p73 transactivates PRODH in mammalian cells
To determine if p63 and p73 were capable of driving
expression of the endogenous PRODH gene in mammalian
cells, expression constructs for p53, p63β, p73β were
transiently transfected into HCT116 p53-/- cells. Cells
transfected with empty vector represented the negative control
and their value was arbitrarily set to 1 to calculate the fold of
induction obtained with the p53 family members expression
constructs. p63β and p73β expressing cells showed a 3-fold
induction of PRODH, while p53 expressing cells showed a 7-
fold induction (Figure 3A). Therefore, all members of the p53
family exhibit the potential to transactivate the endogenous
PRODH gene in mammalian cells. To determine if PRODH was
a physiological target of the whole p53 family we investigated
PRODH expression resulting from genotoxic stress-induced
modulation in cells lines that are mutant or null for p53 but
express endogenous p63 or p73. Two cell lines, MDA-MB-231
and Rh30, were chosen to investigate the impact of p73 on
PRODH expression. MDA-MB-231 is a breast carcinoma-
derived cell line expressing the p53 p.R280K mutant. This
mutant is considered to be loss-of-function based on the
expression of physiological p53 targets and on functional
assays in reconstituted systems (http://p53.fr/) [42]. The cells
are reported to express TAp73β but no p63 [43]. Treatment
with DOXO resulted in induction of the PRODH gene at levels
comparable to P21 and NOXA, used as positive controls
(Figure 3B). The rhabdomyosarcoma-derived Rh30 cell line
was also investigated for PRODH expression. This cell line
Table 1. p53 Response elements in the PRODH gene.
 Name
Location (bp
from TSS) Mismatches HS 1Mismatches HS 2 Spacer (bp) Sequence
1 -3.1 Promoter,-3,158 1 2 5 cGACTTGTCCTCAATGAcCAcGCTC
2 -0.9 Promoter, -917 - 1 in ¼ site, 3 in aHS 7, 5 CACCAGgCTCCACTATGGGCTTGTCTTCGTGtGACTTcTgT
*
3 +1.7 Int 2,+1,694 2 1 - GGGCAAGgaCGGGCATGCTa
4 +2.8 Int 2,+2,816 2, 2, 2, 2, 3 in each of the 5 HS 3,0,0,3 bprespectively ttACAAGCCCTAGGctCATGCCTAGGCATGgTgGctCATGCCTGTAAttCTAGCaC °
5 +4.7 Int 2,+4,727 3 - 3 GtcCTTGTTgCCAGGGCATGCCT
6 +6.4 Int 3,+6,453 1 2 8 GGtCTTGCTCTGTTGCCCAGGCTAGagT
7 +6.8 Int 3,+6,817 - 2 - AGGCTTGCCTcAGCATGTCg
8 +14.3 Int 8,+14,269 2 1 2 AGcCATGgTTCCAGcCAAGCCC
9 +15.8 Int 9,+15,832 - in ¼ site 1 5 TGTTTGTTAGAAGCATGTCa
HS: half-site
*. same RE described in [38].
° Cluster formed by 5 half-sites: the 3 central half-sites contain a CATG core and are separated by 0 bp spacer, while the two external half-sites are separated by the central
3 half-sites by 3 bp spacers. All of the 5 half-sites contain at least 2 mismatches each, although they never involve the core of the consensus.
Bold name: REs selected for experimental validation
Bold/underlined: bases belonging to the indicated RE; italic: spacers; minuscule: mismatches within RE
PRODH and PRODH2 Regulation by p53 Family Members
PLOS ONE | www.plosone.org 6 July 2013 | Volume 8 | Issue 7 | e69152
expresses the p53 p. R280S mutant that is described as a loss-
of-function allele as well (http://p53.fr/). The cells are reported
to express TAp73β [43]. PRODH expression was induced by
DOXO treatment at even higher levels than NOXA (Figure 3B).
We were unable to see an induction of P21 in this cell line at
the conditions tested.
Three additional cell lines were instead used to explore
PRODH responsiveness to endogenous p63: HaCat cells,
derived from immortalized keratinocytes, and two cell lines
derived from head and neck squamous cell carcinomas,
namely JHU-029 and JHU-011. HaCat are compound
heterozygous for two p53 mutations [H179Y and R282W, the
former retaining residual transactivation function, while the
latter being a loss-of-function allele (http://p53.fr/)]. These cells
abundantly express ΔNp63α. JHU-029 and JHU-011 cells
contain frameshift and nonsense p53 alleles, respectively, and
do not express p53 proteins, based on western blot analysis
(Figure 3C). Both cell lines express ΔNp63α; JHU-029 also
expresses p73. Although ΔNp63α is not the most
transactivation competent p63 isoform, it is commonly
expressed in adult tissues as well as tumors, and specifically in
squamous epithelial cells where is important for the regulation
of specific target genes [44]. In all the three cell lines a
reduction of p63 protein levels upon DOXO treatment was
observed. mRNA expression analysis did not identify
modulation of PRODH gene expression in HaCat cells. The
reported ΔNp63α target gene COL18A1 [45] was instead
repressed, consistent with the reduction in ΔNp63α protein
levels. P21 appeared to be slightly induced, which could be
related to a reduction of ΔNp63α-mediated repression [46]
Figure 2.  The PRODH gene contains several putative p53 REs, some of which are differentially transactivated by p53
family members in yeast.  A. Scheme depicting chromosomal location and sequence of the six p53 REs in the PRODH gene that
were selected for further analyses. The sequence of the REs at the various locations is shown (lowercase = mismatches from
consensus; italics = spacer between half-sites) B. The REs in the PRODH gene were assayed with different p53 family members
(p53, p63β and p73β) at different levels of galactose induction (0.008%, lighter bars and 1%, darker bars) in the yeast
transactivation assay. As a positive control, the yeast strain carrying one of the p53 REs present in P21 gene (P21-5’) was included.
Bars represent the fold of induction obtained on each RE by the specified p53 family expression construct over the values obtained
with the relative empty vector (negative control) (set to 1 and indicated by a broken line across each graph) used as negative
control. The experiments shown derive from at least three biological replicates.
doi: 10.1371/journal.pone.0069152.g002
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Figure 3.  At least two p53 family members control the expression of PRODH in mammalian cells.  A. Analysis of PRODH
transcript levels after ectopic expression of p53 family members p53, p63β, p73β. Expression constructs for p53, p63β, p73β were
transfected in HCT116 p53-/- cells and PRODH transcript induction was assayed by qPCR and compared to the empty vector, used
as reference and indicated by the broken line. B–D. Analysis of PRODH expression by qPCR in the indicated cell lines treated with
DOXO and compared to untreated controls. Western blots of relevant proteins and of β-actin or β-tubulin used for normalization are
shown. Variation of the relevant protein(s) in DOXO treated samples, compared to controls, after taking into account normalization
with β-actin or β-tubulin, is reported above the western blots; for panel D, both TAp63 isoforms were quantified and the arrowheads
indicate the TAp63α isoform and its quantification. B. Rh30 and MDA-MB-231 cell lines, expressing mutant p53 and TAp73β; C. cell
lines with mutant (HaCat) or null (JHU-029, JHU-011) p53 and expression of ΔNp63α (HaCat, JHU-029, JHU-011); D. the Mahlavu
hepatocarcinoma cell line, expressing mutant p53 and TAp63 isoforms. All the experiments shown are representative of at least
three biological replicates.
doi: 10.1371/journal.pone.0069152.g003
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following the decrease in p63 protein levels after DOXO
treatment. PRODH was differently regulated in JHU-029 and in
JHU-011 cell lines: slightly induced in JHU-029, but repressed
in JHU-011, consistent with the reduction of p63 protein (Figure
3C). Confirming previous reports [28], P21 was inducible both
in JHU-029 and in JHU-011, which could be p73-dependent.
COL18A1 was instead repressed in both cell lines, paralleling
the reduced level of p63 protein. Taken together, our results
are supporting p73-mediated induction of PRODH, while the
data obtained with the cell lines expressing ΔNp63α are less
conclusive and univocal.
Finally, PRODH expression was analyzed in the Mahlavu
hepatocellular carcinoma cell line after DOXO treatment.
Mahlavu cells express the p53 p. R249S mutation, that retains
very low residual activity based on functional assays in
reconstituted systems (http://p53.fr/). These cells were reported
to constitutively express TAp63α. Importantly, after treatment
with DNA damaging agents all TAp63 isoforms were reported
to be induced, although only a limited number of targets was
shown to be subsequently activated, resulting preferentially in
G2/M arrest [47]. In our experiments, based on western
blotting, both TAp63α and TAp63β were expressed in Mahlavu
cells and both were only slightly induced by DOXO (Figure 3D).
While P21 was induced after DOXO in this cell line, as
previously reported [47], and so was NOXA, we were unable to
see any induction of either PRODH or PUMA (Figure 3D). This
differential target expression may be due to a residual,
selective activity of the specific p53 mutant expressed in this
cell line or may be cell type or cell line specific. More TAp63
expressing cell lines, possibly deriving from other cell types,
should be tested before drawing any definitive conclusions on
endogenous p63 mediated PRODH transactivation.
5. The +6.8 RE shows the highest p53 binding in vivo
To study p53 binding to the PRODH gene in vivo, HCT116
p53+/+ cell line and its p53 knockout derivative (HCT116 p53-/-),
were treated with DOXO or left untreated (mock) and cell
extracts were subjected to ChIP analysis.
The data showed that the +2.8 and the +6.8 REs were the
sequences most efficiently bound by p53 in HCT116 p53+/+
after DOXO treatment, showing a 2-fold or higher enrichment,
respectively, when compared to the p53 immunoprecipitated
material in mock conditions and in the DOXO treated HCT116
p53-/- cells (Figure 4A). To determine specificity of p53
enrichment at each RE after DOXO treatment we also applied
a cutoff, choosing the highest value obtained for binding of p53
at a genomic region not containing a p53 RE (an average of
the signal with beta-actin and CCNB1 genes, indicated as No
Binding Site, NBS) (Figure 4A). Given the high level of p53
bound to the NBS site, the +1.7 and +4.7 REs, although
enriched in bound p53 after DOXO when compared to the
other conditions at the same locus, could not be considered as
positive (Figure 4A).
To verify whether p53 binding to PRODH regulatory
elements was a general and physiological response to DNA
damage, we repeated ChIP experiments in the breast
adenocarcinoma cell line MCF7, expressing wild-type p53. To
control for specificity of p53 binding, IgG was used and the
binding of DO-1 or IgG to the specific REs or the NBS in
stressed (DOXO) or mock conditions was compared. PRODH
-3.1, +2.8, +4.7 (despite a high background in control
conditions as well), +6.8 and, at a minor extent, -0.9 REs were
enriched in p53 immunoprecipitated material after DOXO
treatment, when compared to IgG immunoprecipitated controls
in the same conditions, and to DO-1 immunoprecipitation in
mock conditions. p53 binding to PRODH REs was confirmed
also when a cutoff, based on binding of IgGs to NBS, was
applied.
In conclusion, our results suggest that two (+2.8 and +6.8 in
HCT116 p53+/+) or more (-3.1, -0.9, +2.8, +4.7, +6.8 in MCF7)
of the p53 REs identified in the PRODH gene are indeed bound
in vivo by p53 and that binding increases upon DNA damage.
6: p53, but not p63 and p73, weakly transactivates from
the PRODH2 REs in yeast
Five putative p53 REs were identified in the PRODH2 gene,
three of which were in the promoter, while two were located in
intron 9 at more than 10 kb from the TSS (first nucleotide
present in the NM_021232.1 reference PRODH2 mRNA)
(Table 2). The latter two REs consisted of just one half-site
(Table 2); for this reason and for the distance from the TSS,
they were excluded from further analysis. Of the three REs
identified in the promoter (Table 2 and Figure 5A), two had a 3
bp spacer and at least four mismatches in the two half-sites,
not involving the core sequence (-1.3 and -0.5), and the third
(-0.27) had a 6 bp spacer and one or two mismatches in the
two half-sites (Table 2 and Figure 5A).
Yeast strains carrying the -1.3, -0.5 and -0.27 REs upstream
of the chromosomally located luciferase reporter, and
otherwise isogenic with the previously described PRODH RE
strains, were constructed. Again, an isogenic strain carrying the
P21-5’ RE was used as positive control. Activity of the reporter
was only slightly increased by high-level p53 expression in the
three PRODH2 strains, with -0.27 being the most efficiently
transactivated (9-fold induction) (Figure 5B). A 4-fold increase
in luciferase activity over the empty vectors, used as negative
control, was obtained with the -1.3 RE but only a 2-fold with the
-0.5 RE. Expression of p63ß and p73ß did not result in any
detectable induction of luciferase activity (Figure 5B). Taken
together the results suggested a weak responsiveness of
PRODH2 gene to p53 and no responsiveness to p63 or p73.
7: p53 weakly transactivates the PRODH2 gene in
mammalian cells
To verify if PRODH2 is inducible by genotoxic stress via p53,
we treated different cell lines known to harbour wild-type p53
with DOXO or 5-FU, as previously described for induction of
PRODH. Consistent with the literature, these genotoxic
treatments resulted in a slight increase of PRODH2 transcript
in LoVo cells, but we were unable to calculate the fold induction
as basal levels fell below the detection limits of our qPCR
(Figure 6A). In HCT116 p53+/+ and MCF7 cell lines, basal levels
were undetectable and no induction was observed (Figure 6A).
Finally, when the HepG2 hepatocarcinoma cell line, which
turned out to have detectable basal levels of PRODH2, was
treated with DOXO, no induction of the PRODH2 gene was
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observed (Figure 6B). Concomitantly, a slight repression was
detected, in spite of efficient induction of the P21 transcript,
used as a positive control.
Taken together, and compared with the induction levels
obtained with PRODH, PRODH2 should be considered as a
weak p53 target with low expression levels and limited p53
responsiveness in human cells.
Figure 4.  Relative p53 occupancy levels at PRODH sites containing p53 REs.  ChIP-qPCR experiments were performed in: A.
HCT116 p53+/+ cell line and its isogenic derivative HCT116 p53-/- (negative control), treated with DOXO or left untreated. The broken
line indicates the level of p53 bound to the No Binding Site (NBS) after DOXO treatment in the HCT116 p53+/+ cells; B. the MCF7
cell line, treated with DOXO or left untreated. As a control for aspecific antibody binding, immunoprecipitation with IgG was also
performed. The broken line indicates the enrichment of IgG immunoprecipitated material over the input, that represents the highest
value obtained for the NBS negative control. The graphs show the binding of p53 to the genomic regions surrounding the REs in the
PRODH gene, as well as the binding to a genomic region not containing a p53 RE (NBS), used as negative control, and to the
genomic region containing the P21-5’ RE (positive control). Data shown are representative of two independent experiments and the
values obtained are expressed as percentage of input.
doi: 10.1371/journal.pone.0069152.g004
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Discussion
In the present study, the identification of putative p53 REs in
the PRODH and PRODH2 genes and the experimental
analysis of their functionality are described. Indeed, these
genes have been previously described as p53 targets
[15,19,38], although the REs were not characterized. They
encode proteins involved in similar but not identical metabolic
processes in the cell. In fact, their catalytic activity is directed
on very similar substrates of common origin (dietary protein or
collagen degradation) with limited cross-reactivity with each
Table 2. p53 Response elements in the PRODH2 gene.
 Name Location (bp from TSS) Mismatches HS 1 Mismatches HS 2 Spacer (bp) Sequence
1 -1.3 Promoter, -1,281 2 2 3 cAGCATGTTgGGAGGACAAGTag
2 -0.5 Promoter, -0,534 2 3 3 ActCTAGCCTGGGcAACAAGagT
3 -0.27 Promoter, -0,267 1 2 6 GtACATGTTTCCTGCTGtcCATGTTT
4 +10.5 Intron 9,+10,519 2 NA NA cAGCAAGaCC
 5 +10.7 Intron 9,+10,685 NA NA AAGCAAGTCC
HS: half-site
Bold: REs selected for experimental validation
Bold/underlined: bases that are part of the indicated RE; italic: spacers; minuscule: mismatches within RE
Figure 5.  The PRODH2 gene contains three putative p53 REs, two of which are poorly transactivated only by p53 in
yeast.  A. Scheme depicting chromosomal location and sequence of the p53 REs in the PRODH2 gene, selected for analysis in the
yeast transactivation assay. B. The REs in the PRODH2 gene were assayed with different p53 family members (p53, p63β and
p73β) at different levels of galactose induction (0.008%, lighter bars and 1%, darker bars) in the yeast transactivation assay. As a
positive control, the yeast strain carrying the P21-5’ RE was included. Bars represent the fold of induction of each RE by the
specified p53 family expression construct over the values obtained with the relative empty vector (negative control) (set to 1 and
indicated by a broken line across each graph). All the experiments derive from at least three biological replicates.
doi: 10.1371/journal.pone.0069152.g005
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other [48]. Furthermore, both proteins are capable of inducing
apoptosis via ROS production [16,19].
In spite of the fact that PRODH has been known for a long
time as a p53 pro-apoptotic effector [15], there is very limited
information on the regulatory elements that mediate p53
responsiveness of the corresponding gene. This could explain
why PRODH was not included in the list of 129 genes
responding to at least three out of four of the criteria -namely
the presence of a p53 RE, up-regulation by wild-type p53,
responsiveness of the identified RE in functional assays and
physical binding of RE by p53-to be classified as a p53
regulated gene [2,49].
Here, we extended the characterization of PRODH
responsiveness to p53 beyond genotoxic induction, by showing
that it was also strongly induced by p53 stabilization following
Nutlin-3A treatment (Figure 1). We also showed, by use of a
yeast transactivation assay, that p53 exhibits transactivation
potential towards all intronic REs identified in the PRODH gene
(Figure 2B). The intronic REs presented at least two complete
half-sites and no mismatches in the core sequences, in
contrast to the REs present in the promoter (Table 1).
Ultimately, the extent of p53-dependent transactivation of the
PRODH gene may be due to the sum of the contribution of
each functional RE. Moreover, depending on p53 levels one
might expect titration of p53 to the REs based on its affinity
resulting in different levels of PRODH induction, which may
influence its activity [17,50,51]. Finally, we showed that some
of the REs identified are directly bound by p53 in vivo.
The only data available in the literature before the present
work reported on a putative p53 binding site in the PRODH
promoter, for which weak p53-dependent transactivation was
shown to be associated with p53 binding [38]. The observed
transactivation based on ectopic p53 overexpression in a p53-
null cell line was very low, less than 2-fold in the first 48 hours
and reached only 3.5-fold 72 hours after transfection [38].
Taking into account the current genome annotation and
position of TSS, this binding site, previously located at position
-1.161 bp, corresponds to the -0.9kb RE (present work), shown
to be inactive in the transactivation assays and poorly bound by
p53 in ChIP analyses in two cell lines. The putative RE
contains a consensus half-site with a rigid, lower affinity CTTG
core motif [52,53], and an additional half-site, separated by a 5
bp spacer that also contains two mismatches in critical
positions. Based on previous studies on the cis-element
requirements for p53-induced transactivation, we would predict
this RE to behave as a single half-site with very low
transactivation potential [37,54]. The very low activity observed
by Maxwell and Kochevar [38] is indeed compatible with the
responsiveness reported for a single p53 half-site [37,55]. In
the yeast-based assay we used, ectopic p53 expression is
controlled by an inducible promoter and the results obtained at
different levels of expression strongly suggest that the putative
RE in the PRODH promoter region is, at best, very weakly
functional (see Figure 2 panel A). In conclusion, PRODH
modulation by p53 seems to be mainly due to the other REs we
identified (Figure 2B and Figure 4). Among these, the +6.8 was
Figure 6.  p53 weakly induces PRODH2 expression in some cell lines.  A. The ability of DOXO to induce expression of the
PRODH2 gene was analysed in four cell lines harbouring endogenous wild-type p53, namely HCT116 (p53+/+), MCF7, LoVo and
HepG2. B. Levels of PRODH2 (darker bars) and P21 (lighter bars, positive control) transcripts in HepG2 cells treated with DOXO
were determined by qPCR. The value obtained in the untreated cell line was normalized to 1 (broken line). All the experiments were
performed in triplicate.
doi: 10.1371/journal.pone.0069152.g006
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the RE most efficiently transactivated by all members of the
p53 family and is embedded in a genomic region well
represented in several genome wide p53 ChIP analyses
[39,40] (D. Menendez and M. Resnick, personal
communication). The genomic region containing the +6.8 RE,
together with the +2.8 RE, was recently reported to be bound
by p53 in the MCF7 cell line, after various treatments [56]. We
found that the same regions were enriched in p53
immunoprecipitated material in both DOXO treated MCF7 and
HCT116 p53+/+ cell lines. In our experimental settings, however,
other REs, among those identified, were bound by p53 in the
MCF7 cell line. These results were mostly consistent with the
ones obtained in the yeast functional assays, confirming the
reliability of the data.
Concerning PRODH2, our results could not conclusively
demonstrate its responsiveness to p53: in fact, the
experimental results suggest that it is at best a very weak p53
target gene. This conclusion is based on the functional analysis
of identified p53 REs in yeast (compare Figures 2 and 5) and
on the quantification of the endogenous gene expression in
different cell lines upon genotoxic stress-dependent induction
of p53 (Figure 6). The latter analysis was limited by the
undetectable basal level of PRODH2 expression in most of the
cell lines that were examined (i.e. HCT116, MCF7, LoVo).
However, in the HepG2 cell line, where a basal level was
clearly detectable, no induction of PRODH2 by activation of
p53 was observed. Recently, the group led by Phang
demonstrated PRODH2 induction by p53 both in RKO and
LoVo cell lines, although basal expression was only observed
in RKO colon cancer cell line [19]. In agreement with their
findings, in the LoVo cell line we could confirm absence of
basal expression but its induction upon genotoxic stress, that
was however at the limit of detection by qPCR. Shinmen et al.
[20] could not detect any induction of PRODH2 upon p53
transfection or stabilization by Nutlin in the U87 glioblastoma-
derived cell line, similar to what we observed in HepG2 cells.
From all these observations, it appears that both PRODH2
basal expression and its induction by p53 are cell line-
dependent (Table S3 and Figure 6). It is possible that
transcription of certain targets by p53 is influenced by the
presence of other transcriptional co-factors in these cell lines
[20].
Interestingly, Nikulenkov et al. found that, after 5FU and
Nutlin3A treatment, p53 weakly bound to a PRODH2 genomic
region [56]. The level of binding was considerably lower than
PRODH or other p53 common targets. The genomic region
differed in the two treatments and mapped about 6.8 and 15.5
kb upstream of the PRODH2 TSS, respectively, a region that
lied outside the genomic range we considered in our analysis,
that started 5kb upstream of TSS. Nevertheless, there is no
evidence that these regions actually control the expression of
PRODH2. In our analyses we did not find PRODH2 induction in
the MCF7 cell line upon genotoxic damage (Figure 6).
In conclusion, although a coordinated expression of PRODH
and PRODH2 would be justified by the existence of proteins,
like collagen, rich both in proline and OH-proline, respectively
the substrates of the two enzymes, this does not seem to be
the case [57]. Indeed, PRODH has a broad pattern of
expression and could contribute to cell metabolism by the
production of glutamate and α-KG from P5C, compounds in
turn involved in many metabolic reactions and pathways in the
cell.
On the lack of a coordinated p53-dependent expression of
PRODH and PRODH2 some considerations can be taken into
account. First, and notably, the step downstream of the
PRODH reaction in the pathway leading from proline to
glutamate is catalyzed by P5C dehydrogenase, whose gene
(ALDH4) was reported as a p53 target [18]. Second, other p53
transcriptional targets, such as TIGAR [58,59], can modulate α-
KG levels. This suggests an important, and only partially
elucidated, contribution of the latter compound in p53 mediated
responses and stresses the contribution of PRODH in the
metabolic pathways controlled by p53 [4].
Finally, in this work we also addressed the responsiveness of
the PRODH gene to other members of the p53 family. Indeed,
we found that ectopic expression of p63β and p73β could also
induce PRODH, even though at lower levels compared to p53
(Figure 2A). We also showed that induction of endogenous
TAp73β by DOXO in two cell lines (Rh30 and MDA-MB-231)
leads to an increase in PRODH transcript (Figure 2B), while
data obtained for p63 were less clear-cut, probably because of
the p53 family members endogenously expressed and their
cross talk. Indeed, three of the cell lines we chose for analyzing
the contribution of p63 to PRODH transactivation (JHU-011;
JHU-029; HaCat) express mainly the ΔNp63α isoform. This
isoform has been shown to be able to transactivate or repress
different subsets of p53 responsive genes as well as a set of
peculiar genes [7,44] and is the p63 isoform commonly
expressed in adult tissues, tumors and tumor derived cell lines
[44]. Interestingly, expression of the ΔNp63α isoform in the
yeast strain carrying the +6.8 RE was capable of driving
luciferase activity in the transactivation assay (unpublished
result). Finally, we found that in the Mahlavu hepatocellular
carcinoma cell line PRODH expression was diminished upon
DOXO treatment. The isoforms expressed, that were found
only slightly induced by DOXO in this cell line, are TAp63α and
TAp63β (Figure 3D), the first of which does not transactivate
the PRODH REs in the yeast assay (unpublished results). We
do not have an explanation for this observation, except
interaction between the different isoforms could impact on their
transactivation ability. More cell lines expressing TAp63 will
need to be examined before drawing any conclusions on
transactivation of PRODH by endogenous p63.
To our knowledge, no data are available on p73 ability to
transcriptionally regulate PRODH expression, while PRODH
had been previously found as one of the genes expressed
more than 4-fold upon expression of a tetracycline-inducible
TAp63γ isoform [60]. The lower levels of induction with respect
to p53 were not unexpected, as several other p53 targets show
a decreased responsiveness to p63 and p73. Furthermore, this
result could be explained, among others, by the fact that p63
and p73 show somewhat different DNA binding affinity and
transactivation potential towards canonical p53 REs, possibly
in part dependent on tetramer assembly and conformation
stability, as recently revealed by the comparison of crystal
structures of p63 and p73 bound to DNA [61–64]. It is
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interesting to note that the three REs transactivated by p63
(namely +1.7, +2.8 and +6.8) and the one responsive to p73
(+6.8) all have at least two half-sites with no spacer, consistent
with previous studies indicating both for p63 and p73 a marked
preference for adjacent half-site REs for both p63 and p73
[14,63,65]. The +6.8kb RE turned out to be the most efficiently
recognized not only by p53 but also by p63 and p73. The
reason for this may be that this RE has no spacer and that the
mismatches present in one half-site affect the first and last
base of the consensus, which are not involved in establishing
direct protein::DNA interactions and does not preclude high
affinity binding of p53 [49,66–68]. However, since in
mammalian cells p63 and p73 transactivate equally the
PRODH gene in transient transfection assay, induction appears
not to be strictly correlated to the relative transactivation
potentials measured in the yeast-based assay. Notably, also
p73, besides p53, has been recently implicated in regulation of
metabolism and autophagy and has been shown to be
regulated by mTOR [43,69,70]. As proline dehydrogenase is
induced by rapamycin [71], it is tempting to speculate that this
may be achieved at least in part through p73.
In conclusion, this work demonstrates that PRODH is a
target of at least two p53 family members and provides new
clues for a deeper involvement of p53 proteins in metabolic
pathways. In fact, in light of the recently described link between
glutamine and proline, p53 acquires a more profound role in
metabolism of these non essential amino acids and their
derivative α-KG and in antagonizing c-Myc, that was recently
found to downregulate PRODH as an important contribution to
metabolic reprogramming and induction of cell proliferation
[72–75].
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